<DOC>
	<DOCNO>NCT02620072</DOCNO>
	<brief_summary>Type 1 diabetes ( T1D ) result autoimmune destruction insulin-producing beta cell . The process autoimmune destruction identify circulate islet autoantibody beta cell antigen , mediate lack immunological self-tolerance . Self-tolerance achieve T cell exposure antigen thymus periphery manner delete autoreactive effector T cell induce regulatory T cell . Immunological tolerance achieve administration antigen appropriate condition . Evidence emerge human approach may effective chronic inflammatory disease multiple sclerosis allergy . Administration oral insulin multiple islet autoantibody-positive child offer potential induce immunological tolerance beta cell thereby protect development progression type 1 diabetes .</brief_summary>
	<brief_title>Fr1da Insulin Intervention</brief_title>
	<detailed_description>Type 1 diabetes ( T1D ) disease predominantly affect child . T1D precede islet autoimmunity , often start early childhood peak incidence around 1 2 year age . Previous study show multiple islet autoantibody indicate point limited return path T1D . Every year , around 10 % multiple islet autoantibody positive child progress islet autoantibody positivity symptomatic T1D . Thus , therapy intervention need change inevitable path insulin dependence . Treated initiate early beta cell still intact autoimmune process less advanced may effective . Administration oral insulin multiple islet autoantibody-positive child offer potential immunological tolerance beta cell thereby protect progression T1D . Previous study rodent indicate mucosal administration insulin effective induce regulatory immune response prevent autoimmune diabetes . Mouse study indicate dose oral insulin important . In human study oral insulin administration show excellent safety profile , without adverse side effect dose 2.5 7.5 mg per day ( 1-3 ) . The administration oral insulin ( 7.5 mg per day ) prediabetic ICA IAA positive first degree relative T1D patient within DPT-1 study show significant beneficial effect intention treat analysis . A sub-analysis data , however , show significant benefit relatives high titer IAA . The Pre-POINT study , first primary autoantigen vaccination dose-finding study child high genetic risk type 1 diabetes administer insulin orally daily test dos ( 2.5 mg ; 7.5 mg ; 22.5 mg 67.5 mg ) show five six child expose dose 67.5 mg insulin evidence antibody T cell response insulin . The response differ typical response see child develop diabetes antibody responses weak affinity T cell response preponderance cell regulatory T cell phenotype ( 37 ) . These result also encourage safety viewpoint indicate oral exposure insulin dose approximately equivalent efficacious dos rodent may promote tolerance child . A secondary prevention study use 7.5 mg oral insulin administer daily currently conduct TrialNet Study Group , include Forschergruppe Diabetes , Klinikum rechts der Isar der Technischen Universität München study site . Autoantibody , normoglycemic subject age 3 45 year treat oral insulin . In currently conduct trial safety issue report thus far . The active substance oral application human insulin , synthesize special non-disease-producing laboratory strain Escherichia coli bacteria genetically alter addition gene human insulin production ( Lilly Pharmaceuticals , Indianapolis , Indiana , USA ) . The physical , chemical pharmaceutical property human insulin well documented manufacturer . Oral Insulin apply capsule contain 7.5 mg active substance together fill substance cellulose dose escalation 67.5 mg active substance together fill substance cellulose . After ingestion , insulin degrade gastric acid . Enteric delivery systemic availability therefore unlikely efficacy active insulin likely restrict oral mucosa . The Fr1da Insulin Intervention Study intend dose oral application 7.5 mg 67.5 mg per day . The aim study determine whether daily administration 67.5 mg insulin young child age 2 year 12 year multiple islet autoantibody alters immune response insulin intervention period 12 month whether alter immune response associate protection develop dysglycemia The immune response oral insulin treatment yet demonstrate indicate protection disease . To address , Fr1da Insulin Intervention Study include dysglycemia co-primary outcome trial , novel data indicate dysglycemia valid outcome path type 1 diabetes . Once dysglycemia present multiple autoantibody positive subject , average time 2 year clinical symptomatic diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Written inform consent sign either parent ( ) legal guardian ( ) . 2 . Children age 2 year 12 year . 3 . Positive least two islet autoantibody autoantibodies glutamic acid decarboxylase ( GAD65 ) , insulin ( IAA ) , autoantibody IA2 ( IA2A ) , autoantibodies zink transporter 8 ( ZnT8A ) ( time screen sample collection randomization must exceed 90 day ) . 4 . Normoglycemia assess oral glucose tolerance test ( OGTT ) . 5 . Participation observational study regularly monitor diabetes development Participants meet follow criterion NOT eligible inclusion study : 1. dysglycaemia overt hyperglycemia ( diabetes ) 2 . Concomitant disease treatment may interfere assessment cause immunosuppression , judge investigator . 3 . Current participation another intervention trial . 4 . Any condition could associate poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>oral insulin</keyword>
	<keyword>oral tolerance</keyword>
	<keyword>autoantigen</keyword>
	<keyword>self tolerance</keyword>
	<keyword>prevention</keyword>
	<keyword>risk develop type 1 diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
	<keyword>dysglycemia</keyword>
</DOC>